Drug Profile
Oxybutynin/pilocarpine - Dermavant Sciences/Theravida
Alternative Names: DMVT 504; pilocarpine/oxybutynin; RVT 504; THVD-102Latest Information Update: 18 Jul 2022
Price :
$50
*
At a glance
- Originator TheraVida
- Developer Dermavant Sciences; TheraVida
- Class Alkaloids; Alkynes; Antiglaucomas; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Furans; Imidazoles; Mandelic acids; Miotics; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperhidrosis
Most Recent Events
- 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization) - Phase-I for Hyperhidrosis in USA (PO)
- 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization)- Phase-II for Hyperhidrosis in Australia (Topical)
- 03 Dec 2021 Phase-I clinical trials in Hyperhidrosis in USA (PO) (Dermavant Sciences pipeline, December 2021)